This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
5-Amino-1MQ (10 mg Vial)
This information is for research and educational use only.
Quick Reference
What is 5-Amino-1MQ?
Research overview based on the cited scientific literature.
• Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.[1][2]
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Storage Instructions
Proper storage preserves compound stability.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
• Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
• Do not refreeze reconstituted solution.
How is 5-Amino-1MQ studied?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)[1]. NNMT is a cytosolic enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability[2].
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis via the salvage pathway, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake[8][9].
What does the research report about 5-Amino-1MQ?
Observations from preclinical and early research literature.
• May support reductions in fat mass while preserving lean muscle in animal models[8][9].
• Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3].
• Enhanced grip strength observed in aged mice when combined with exercise[10].
• Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
• Long-term human safety data not established; this compound remains investigational.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on 5-Amino-1MQ?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.